aidsmap news story
Taking HIV treatment once a week may make it easier to fit into everyday life and reduce the daily reminder of living with the virus. In the ISLEND-2 study, most people who switched from daily treatment to an investigational weekly tablet containing islatravir and lenacapavir favoured their new regimen and the reasons for this went beyond convenience.
These findings were reported in two poster presentations from the ISLEND-2 trial at HIV Glasgow 2026 this week. Dr Moti Ramgopal and colleagues assessed treatment preferences, satisfaction and quality of life after a year. A separate poster by Professor Chloe Orkin and colleagues looked at participants’ and healthcare providers’ experiences through interviews.
Because both drugs are cleared slowly and remain in the body for a long time, longer dosing schedules are possible. The combination could become the first complete HIV treatment taken as a once-weekly pill.
Read the full news story here.
View all aidsmap reports from HIV Glasgow 2026
Source : aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.